The increasing volume of ambulatory surgical procedures, primarily owing to their cost effectiveness is expected to drive the adoption of anesthesia drugs. For instance, in 2015, according to research studies published in the US, the number of outpatient surgeries performed by ambulatory surgical centers (ASCs) stood in the range of 7.4-7.8 million.The growing cases of chronic conditions such as respiratory and cardiac disorders will drive the market growth. For instance, according to the CDC 2014, chronic obstructive pulmonary disease (COPD) was the third leading cause of death in the US in 2014. In addition, 15.7 million individuals in the US have been diagnosed with COPD in 2014.The market is expected to witness high adoption of propofol, owing to its increased advantages over conventional anesthetics. For instance, propofol has rapid onset of action, which increases patient compliance and adherence.Growing focus of vendors toward the development of anesthetics for new ROAs will drive the adoption in emerging applications such as pediatric and dental. For instance, in October 2016, St. Renatus launched Kovanaze, a nasal-administered dental anesthetic.Increasing inorganic growth strategies of vendors will help expand their presence in the market and leads to further consolidation. For instance, in June 2016, Aspen completed the acquisition of AstraZeneca's anesthetic portfolio outside the US. The acquisition enabled Aspen to enhance its anesthetic drugs with products such as Diprivan, EMLA, Naropin, and Xylocaine.

如需全文请联系027-87841457.

PART 01: Executive summary 6

PART 02: Scope of the report 18

PART 03: Research Methodology 23

PART 04: Introduction 26

Key market highlights 26

Highlights 27

PART 05: An overview of anesthesia 28

PART 06: Key clinical trials 31

PART 07: Market landscape 32

Market overview 32

Five forces analysis 35

PART 08: Market segmentation by ROA 36

Parenteral 36

Inhalational 38

Others 39

PART 09: Market segmentation by type 41

General anesthesia 41

Local and regional anesthesia 41

PART 10: Geographical segmentation 42

Anesthesia drugs market in Americas 43

Anesthesia drugs market in EMEA 45

Anesthesia drugs market in APAC 47

PART 11: Market drivers 49

Growing volume of surgical procedures 49

Increasing cases of chronic conditions such as

respiratory diseases and cardiac disorders 50

Increasing demand for propofol 51

PART 12: Impact of drivers 53

PART 13: Market challenges 54

Lack of skilled anesthesiologists 54

Side effects coupled with product recalls 55

Drug shortages coupled with fiscal cliff 56

PART 14: Impact of drivers and challenges 57

PART 15: Market trends 58

Increase in M&A 58

Growing focus on oral medications to expand reach for

pediatric population 59

Growing focus on developing anesthetics for new ROA 60

PART 16: Vendor landscape 61

Competitive scenario 61

PART 17: Key vendor analysis 66

AbbVie 66

Aspen 68

Baxter 73

B. Braun 76

Fresenius Kabi 78

Other prominent vendors 80

PART 18: Appendix 83

List of abbreviation 83

PART 19: Explore Technavio 84